44: Pre-clinical study of the effect of the As-sig-TAA/ecdCD40L vector prime-TAA/ecdCD40L protein boost vaccine in elderly recipients for suppression of recurrent cancer following allografting and donor lymphocyte infusions (DLI)  by Tang, Y. et al.
proliferate, express KIR and NKG2A receptors and develop cyto-
toxic and cytokine-producing potential. Umbilical cord blood, a
site of developing hematopoiesis, contained a signiﬁcantly higher
percentage of CD56dim NKG2A-KIR- cells (59 	 11%) support-
ing the notion that these cells are developmentally immature. We
conclude that lineage-committed NK cells in the blood do not
require inhibitory self-tolerance mechanisms until they reach a late
stage of differentiation.
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PRE-CLINICAL STUDY OF THE EFFECT OF THE AS-SIG-TAA/ECDCD40L
VECTOR PRIME-TAA/ECDCD40L PROTEIN BOOST VACCINE IN ELDERLY
RECIPIENTS FOR SUPPRESSION OF RECURRENT CANCER FOLLOWING
ALLOGRAFTING AND DONOR LYMPHOCYTE INFUSIONS (DLI)
Tang, Y.1, Akbulut, H.1, Maynard, J.1, Petersen, L.1, Deisseroth, A.1
1Sidney Kimmel Cancer Center, San Diego, CA.
The mini-allogeneic transplant has opened the door to treat-
ing individuals in the ﬁfth and sixth decades of life. Unfortu-
nately, matched related donors for these individuals usually have
an aged immune system in which the immune response has been
impaired by a reduction in the ratio of antigen naı¨ve/memory
CD4 and CD8 T cells and acquired functional defects in acti-
vated “helper” CD4 T cells (eg diminished CD40 ligand
(CD40L) expression). This has limited the applicability of mini-
allografts to older individuals and to the use of post allograft
vaccines to expand speciﬁc populations of CD8 effector cells to
bolster the anti-cancer and anti-viral immune response. Our
laboratory has developed an adenoviral vector (Ad-sig-TAA/
ecdCD40L) vaccine which is designed for the in vivo target
associated antigen (TAA) loading and activation of dendritic
cells (DCs), and to overcome the absence of CD40L expression
in activated CD4 helper T cells in older individuals. The sub-
cutaneous (sc) injection of this vector leads to the release of a
fusion protein composed of a TAA linked to the extracellular
domain (ecd) of the CD40 ligand (CD40L), which binds to the
CD40 receptor on DCs, activates the DCs, and leads to the
presentation of TAA fragments on Class I MHC. VPP vaccine
overcomes anergy in TAA.Tg transgenic mouse, and induces
TAA speciﬁc memory cells. Two sc injections of the TAA/
ecdCD40L protein as a booster following the sc administration
of the Ad-sig-TAA/ecdCD40L vector (VPP) expands the mag-
nitude of the cellular and humoral immune response induced by
the vector in 18 month old aged mice as well as in younger mice.
This vaccine decreased levels of negative regulatory CD4
FOXP3 T cells in tumor nodules. We administered TBI and an
allogeneic stem cell transplant 7 days post sc injection of the E7
positive TC-1 cells. DLI from an Ad-sig-E7/ecdCD40L vector
prime-E7/ecdCD40L protein boost vaccinated donor were in-
jected iv 3 days post transplant, and a single E7/ecdCD40L
protein boost sc vaccination one week thereafter. We found that
the growth rate of the E7 positive TC-1 tumor cells post
allograft was less in the vaccinated than in the control (injection
of tumor cells followed in 7 days by TBI), or the animals in
which the allograft recipient was vaccinated without DLI. Thus,
the use of DLI from VPP vaccinated allodonor decreased tumor
cell growth post allograft.
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DIRECT ISOLATION AND INFUSION OF DONOR-DERIVED CMV-SPECIFIC
T CELLS FOR TREATMENT OR PROPHYLAXIS OF CMV INFECTION
FOLLOWING ALLOGENEIC TRANSPLANTATION
Lowdell, M.W.1, Thomson, K.1, Julie, A.1, Pang, K.1, Samuel, E.1,
Desborough, M.1, Mackinnon, S.1 1Dept of Haematology, Royal Free &
UCL Med Sch, London, United Kingdom.
Reactivation of CMV is common following allogeneic HSCT
and virus-speciﬁc T lymphocytes are necessary for control.
CMV-speciﬁc donor T cell infusions have been used but most
methods involve several weeks of ex-vivo culture. The current
method involves a 20hr incubation of donor peripheral blood
mononuclear cells with rCMV-pp65 protein. Isolation of inter-
feron-gamma positive T cells by CliniMACS using IFN cap-
ture microbeads (Miltenyi Biotec) provides a CMV-reactive T
cell product which is cryopreserved in dosed aliquots for sub-
sequent infusion. A single arm phase I study is underway, with
CMV-T cells given pre-emptively at ﬁrst detection (by qPCR)
of CMV DNA in peripheral blood, or at day 40-50 as pro-
phylaxis. A dose of 1104 CD3/kg recipient weight is infused
and CMV monitored by weekly PCR. Antiviral drug therapy
commences if the viral load rises above our institutional thresh-
old. 12 patients have received CMV-T cells at a median of 4
weeks post HSCT and 9 are alive and well. None experienced
infusion-related toxicity and no deaths were associated with
CMV-T cell treatment or CMV disease. Incidence and severity
of GvHD was no different from historical controls. The median
yield of CMV-T cells following enrichment was 5.2106 (range
0.29-26.7) of which 24.7% were CD4/IFN and 11.2% were
CD8/IFN; a total mean CMV-reactive cell yield of 2.2
106 per donor. Following infusion, in vivo expansion of
CMV-T cells was seen in all patients. CMV-T cells averaged
9.8% of CD4 cells and 8.1% of CD8 cells by 2-4 weeks
post-infusion; the result of in vivo expansions of CMV-reactive
cells of up to 5000-fold. 9 patients received antiviral therapy for
CMV reactivation but in 5 patients this was required for a
signiﬁcantly shorter period than in historical controls (11-14
days). 3 patients had a second CMV reactivation. 1 patient
showed substantially delayed expansion of CMV-T and required
prolonged anti-viral treatment (33 days). 1 required antiviral
drug treatment, the second received no treatment and cleared
virus after a further in vivo expansion of CMV-T cells, suggest-
ing the presence of a functional memory population. 3 patients
were treated prophylactically at day 40-50 and expansions of
CMV-reactive T cells were seen in all 3 despite lack of detect-
able viral DNA in peripheral blood. This technique rapidly
provides clinical-grade CMV-reactive CD4 and CD8 T cells
which appear to provide effective antiviral immunity.
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THYMIC SHIELDING (TS) IN RECIPIENTS OF TOTAL BODY IRRADIA-
TION (TBI) AND ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL
TRANSPLANT (AD-HSCT): REDUCED RISK OF OPPORTUNISTIC INFEC-
TION IN PATIENTS WITH FANCONI ANEMIA (FA)
MacMillan, M.L.1, Blazar, B.R.1, DeFor, T.E.1, Dusenbery, K.R.1,
Wagner, J.E.1 1University of Minnesota, Minneapolis, MN.
Delayed immune reconstitution and consequent opportunistic
infections remain major obstacles to the successful application
of HSCT, particularly in older patients, those with HLA mis-
matched donors and in selected diseases, such as FA. Based on
preclinical work suggesting that TS may improve immune re-
constitution in recipients of TBI and allogeneic HSCT (J Im-
munol 1987:139:358), we evaluated the safety and potential
efﬁcacy of TS in FA patients. After CT localization of the
thymus, 5HVL cerrubend blocks were fabricated and used to
shield the thymus. Otherwise all patients received the standard
preparative regimen consisting of ﬂudarabine 175 mg/m2, cy-
closphosphamide 40 mg/kg, single fraction TBI 450 cGy, and
antithymocyte globulin, with cyclosporine and short course
methylprednisolone as GVHD immunoprophylaxis. In order to
assess the potential risks and beneﬁts of TS, we compared
transplant outcomes of these FA patients who received TS to FA
patients treated with the exact same preparative regimen with-
out TS. Between April 1999-June 2006, 59 FA patients under-
went AD-HSCT at the University of Minnesota; 16 patients had
TBI with TS and 43 had TBI without TS. For those with and
without TS, donors were HLA matched (n42) or mismatched
(n17), and stem cell sources were T cell depleted bone marrow
(n9 vs n38) or umbilical cord blood (n7 vs n5). While
excess graft failure was considered to be the principal toxicity
risk in recipients of TS, incidence of engraftment was similar in
those with and without TS (94% vs 97% respectively, p.46).
Although not statistically signiﬁcant, survival at one year was
higher in FA patients with TS (67% vs 53% respectively,
p.46). However, as shown, TS was associated with a signiﬁ-
cantly lower risk of all three categories of opportunistic infec-
tion after HSCT (Table 1).
Oral Presentations 19
